-+ 0.00%
-+ 0.00%
-+ 0.00%

Verrica Pharmaceuticals Reports 16.7% Sequential Growth In Q1 2025 With Over 10,000 YCANTH Dispensed Applicator Units And Expects Revenue To Align With Normalized Distributor Inventory Levels

Benzinga·04/07/2025 12:04:32
Listen to the news

– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter –

– As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue –

WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicator units increasing to 10,102 in the first quarter. This first quarter growth represents a sequential increase of 16.7% over the fourth quarter of 2024 (8,654 dispensed applicator units).